ASH Clinical News ACN_4.10_FULL ISSUE web | Page 9

We’re excited to bring our
EXPLORER’S
EXPLORER
S SPIRIT
TO THE CHALLENGES OF
MYELOFIBROSIS
At Celgene, we’re working to develop therapies for patients with limited treatment
options in areas of high unmet medical need. With our focus on myelofibrosis, we’re
building on our unwavering commitment to hematologic malignancies and to improving
the lives of patients worldwide.
© 2018 Celgene Corporation 07/18 US-CLG-18-0182